Hyperspectral imaging to map retinal and optic nerve structures
Official title: Defining Retinal Structures Using Hyperspectral Retinal Imaging
Run by Center for Eye Research Australia · NCT07555574 · Data updated 2026-11-12
This study will test whether hyperspectral retinal imaging can detect disease-related features in adults with diabetic retinopathy, glaucoma, age-related macular degeneration, and in healthy volunteers.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Center for Eye Research Australia Academic / other |
| Locations | 1 site (Melbourne, Victoria) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | December 30, 2028 |
| Study ends | December 30, 2028 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT07555574 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older who can provide informed consent and either have a diagnosed retinal or optic nerve condition (for example diabetic retinopathy, glaucoma, or age-related macular degeneration) or are age- and sex-matched healthy controls willing to attend the Centre for Eye Research Australia.
✕Probably not a fit
Participants with dense media opacities (like dense cataract or severe corneal opacity), vitreous haemorrhage, or those unable to undergo pupil dilation may not benefit because adequate hyperspectral imaging cannot be obtained, and the study offers no therapeutic intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will image about 1,000 adults at the Centre for Eye Research Australia using hyperspectral cameras alongside standard ophthalmic imaging such as OCT and fundus photography. Hyperspectral imaging captures retinal reflectance across more than 25 wavelength bands to create a spectral hypercube that may reveal tissue features not seen on conventional colour photos. Images will be processed with registration and spectral normalisation, and pixel-level signatures will be analysed using statistical and machine learning methods. Results will be compared with established imaging biomarkers to determine how well hyperspectral signatures distinguish different retinal and optic nerve conditions.
Why it matters
Potential benefit: If successful, hyperspectral imaging could enable earlier or more precise, non-invasive detection and characterisation of retinal diseases.
How similar studies have gone: Early pilot studies and preclinical work have shown promise for hyperspectral retinal imaging to reveal novel biomarkers, but large-scale clinical validation remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 years and older * Able to provide informed consent * Willing and able to attend a study visit at the Centre for Eye Research Australia * Participants with diagnosed retinal or optic nerve disease (e.g., diabetic retinopathy, glaucoma, age-related macular degeneration) * Age- and sex-matched healthy control participants without known retinal or optic nerve disease Exclusion Criteria: * Inability to provide informed consent * Ocular conditions preventing adequate retinal imaging (e.g., dense cataract, severe corneal opacity, vitreous haemorrhage) * Known contraindication to pharmacological pupil dilation * History of narrow anterior chamber angle or risk of angle closure glaucoma where dilation is considered unsafe * Any condition that, in the investigator's opinion, would compromise participant safety or image quality
Where it's running
-
The Centre for Eye Research Australia
Melbourne, Victoria, Australia Recruiting
Study contacts
- Study coordinator: Darvy Dang
- Email: darvy.dang@unimelb.edu.au
- Phone: +61 3 9959 0102
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Vision screening in general practice to catch preventable sight loss in people over 70
This project will test a GP-based vision-screening program for people aged 70 and older with at least one chronic condition to find sight problems early.
-
Improving follow-up after an eye screening referral
This trial tries text message or health worker reminders to help people referred after an eye screening get to their hospital appointment within 21 days.
-
Community-based eye screening program to prevent blindness
This study is testing whether a community eye screening program in Nepal can help prevent avoidable blindness by catching eye problems early.
-
High Resolution Imaging OCT Study
This study tests whether two investigational OCT devices (R1 and HighRes OCT) produce better image quality than the standard Spectralis in adults with normal eyes or with AMD, diabetic retinopathy, or other retinal diseases.
-
Watching a short video before anti-VEGF eye injections
This trial will test whether watching a brief procedural video before a first anti-VEGF intravitreal injection helps people with retinal diseases feel less anxious and have fewer or smaller subconjunctival hemorrhages.
-
New peptide therapy for retinal diseases
This study is testing a new peptide therapy to see if it can help adults with retinal diseases like age-related macular degeneration and diabetic retinopathy improve their vision and eye health.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.